Compare CVS Health Corp (CVS) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Las Vegas Sands Corp. — how do they compare? CVS Health Corp trades at $86.82 (market cap $112.49B), while Las Vegas Sands Corp. trades at $36.46 (market cap $23.19B). The key difference: CVS Health Corp is far larger — about 4.9× Las Vegas Sands Corp.'s market cap, and Las Vegas Sands Corp. pays the higher dividend (3.35%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Las Vegas Sands Corp. for 72 Days on average.
| CVS | LVS | |
|---|---|---|
Market Cap | $112.49B | $23.19B |
Volume | 8,467,392 | 4,822,073 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $69.49 |
52-Week Low | $70.08 | $35.81 |
Typical Hold Time | 83 Days | 72 Days |
Enterprise Value | $174.83B | $35.08B |
Dividend Yield | 3.02% | 3.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
LVS trades at $36.10, down 0.58% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth from $13.02B in 2025 to projected $13.7B in 2026, with consistent profitability margins around 12.5%. Recent news highlights Sands China's community initiatives and environmental certifications, supporting long-term positioning in Macao's tourism market.
Wall Street maintains strong bullish sentiment with 59% buy ratings and a $59.78 price target representing 66% upside potential. Key risks include high debt levels (73.15% debt-to-asset ratio) and Macao regulatory exposure. The current valuation at 13.88 P/E appears attractive relative to growth prospects, though technical indicators suggest near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
